| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327506 | Gynecologic Oncology | 2005 | 5 Pages |
Abstract
The 9-AC at this dose and schedule showed limited activity comparable to that seen with other agents in platinum-resistant ovarian or primary peritoneal cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
David Scott Miller, John A. Blessing, Steven Waggoner, Jeanne Schilder, Joel Sorosky, Jeffrey Bloss, Russell Schilder,